UNSPSC 51282133: Moxalactam disodium

This classification denotes a beta-lactam antibiotic with the molecular structure C20H18N6O9S.2NA, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier, 5APW73W3QZ chemically known as 5-oxa-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid, 7-((carboxy(4-hydroxyphenyl)acetyl)amino)-7-methoxy-3-(((1-methyl-1h-tetrazol-5-yl)thio)methyl)-8-oxo-, disodium salt, but more commonly known as moxalactam disodium, which bears US NIH Compound Identifier 47500.

UNSPSC 51282133 Moxalactam disodium, a Commodity code, nominally covers a specific beta-lactam antibiotic; however, the recent state and local opportunities posted under this code show little direct alignment with moxalactam procurement. The recent activity tagged to this code reflects purchases of other pharmaceutical products—antibiotic tablets (Doxycycline, Ciprofloxacin) and naloxone with drug deactivation systems—rather than moxalactam itself. State and local health departments and county public health authorities are the primary issuing bodies, typically accessing pharmaceuticals through piggyback contracts with established cooperative purchasing consortiums such as MMCAP Infuse or through direct competitive bidding on fixed-term supply agreements.

Recent opportunities include an Illinois Department of Public Health piggyback pharmaceutical warehouse award to Chartwell Rx LLC (posted August 28, 2026; response deadline September 11, 2026) for antibiotic tablets valued at $2.99 million over three years, and a Seminole County, Florida IFB for annual naloxone and drug deactivation systems procurement (posted June 30, 2026; response deadline July 26, 2023). Geographic activity is concentrated in Illinois and Florida among recent postings. The mismatch between the code's nominal scope and what is actually being solicited—antibiotics and public health emergency response supplies rather than moxalactam specifically—suggests that this code sees limited direct procurement activity for the named product at the state and local level, or that procurement offices are applying the code inconsistently to broader pharmaceutical categories.